Bright Minds Biosciences Inc
CNSX:DRUG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (12.3), the stock would be worth CA$-25.84 (121% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -57.7 | CA$121.62 |
0%
|
| Industry Average | 12.3 | CA$-25.84 |
-121%
|
| Country Average | 10.2 | CA$-21.46 |
-118%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
1.2B CAD | -57.7 | -60 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 14 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 14 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 11.9 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 20.7 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 13.1 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 40.2 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 10.5 | 30.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7 |
| Median | 10.2 |
| 70th Percentile | 14.5 |
| Max | 13 731.1 |
Other Multiples
Bright Minds Biosciences Inc
Glance View
Bright Minds Biosciences, Inc. is a biotechnology company, which engages in developing therapeutics to improve the lives of patients with severe and life-altering diseases. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-02-08. The firm is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy and pain. The firm has a portfolio of serotonin agonists designed to target neurocircuit abnormalities to treat disorders, such as resistant epilepsy, treatment resistant depression, post-traumatic stress disorder (PTSD), and pain. The company is focused on developing a line of serotonergic 5-Hydroxytryptamine (5-HT) drug candidates that target the 5-HT2C, 5-HT2A and 5-HT2A + 5-HT2C receptors. Its offers 5-HT2C for the treatment of dravet syndrome and behavioral disorders. Its offers 5-HT2A for treatment of depression and other neuropsychiatric disorders. Its offers 5-HT2A + 5-HT2C for several chronic pain disorders/neuropathic pain syndromes, including cluster headaches and chemotherapy-induced peripheral neuropathy.
